Compare · MOVE vs TMDX
MOVE vs TMDX
Side-by-side comparison of Corvex Inc. (MOVE) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOVE and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.50B, about 7.2x MOVE ($345.4M).
- Over the past year, MOVE is up 121.2% and TMDX is down 31.3% - MOVE leads by 152.5 points.
- MOVE has been more active in the news (8 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (18 ratings vs 0 for MOVE).
- Company
- Corvex Inc.
- TransMedics Group Inc.
- Price
- $12.54-3.54%
- $72.31+1.53%
- Market cap
- $345.4M
- $2.50B
- 1M return
- -42.75%
- -6.89%
- 1Y return
- +121.16%
- -31.29%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 8
- 5
- Recent ratings
- 0
- 18
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest MOVE
- SEC Form EFFECT filed by Corvex Inc.
- SEC Form 424B7 filed by Corvex Inc.
- Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations
- SEC Form S-1 filed by Corvex Inc.
- Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)
- Co-Chief Executive Officer Crystal John Adler Iii converted options into 4,053,677 shares, increasing direct ownership by 109% to 6,414,723 units (SEC Form 4)
- Director Fairbairn Emily converted options into 1,205,282 shares (SEC Form 4)
- Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Fairbairn Emily was granted 135,800 shares, increasing direct ownership by 146% to 228,577 units (SEC Form 4)
- CFO Moreland Christopher was granted 523,211 shares (SEC Form 4)
Latest TMDX
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)